NCT03895034CompletedNot Applicable
A Single Center Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- RxSight, Inc.
- Enrollment
- 66
- Locations
- 1
- Primary Endpoint
- Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better
Study Overview
Brief Summary
The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Must sign a written Informed Consent form and be willing to undergo cataract surgery for unilateral or bilateral implantation of the RxLAL.
- •Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.
- •Study eye must have cataract causing reduction in best corrected distance visual acuity (BCDVA) to a level of 20/32 or worse with or without a glare source.
- •Willing and able to comply with the requirements for study specific procedures and visits.
Exclusion Criteria
- •Study eye with pseudoexfoliation.
- •Study eye with diabetes with any evidence of retinopathy.
- •Study eye with evidence of glaucomatous optic neuropathy.
- •Study eye with history of uveitis.
- •Study eye with prior history of Intacs, Radial keratotomy (RK), Conductive keratoplasty (CK), Astigmatic keratotomy (AK), Phakic Implantable Collamer Lens (ICL), Corneal Inlay, or with previous pterygium excision unless the pterygium did not extend more than 2mm onto the cornea from the limbus.
- •Subjects taking systemic medication that may increase sensitivity to UV light.
- •Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
- •Study eye with history of ocular herpes simplex virus.
- •Study eye with history of a congenital color vision defect
Arms & Interventions
Light adjustable lens (LAL) and Light Delivery Device (LDD)
Experimental
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD) (Device)
Outcomes
Primary Outcomes
Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better
Time Frame: 3 months post op
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)CataractsNCT00845520Calhoun Vision, Inc.74
Completed
Not Applicable
Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive SurgeryAphakiaCataractNCT03660865RxSight, Inc.105
Terminated
Not Applicable
A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of FocusPresbyopiaAphakiaCataractNCT04177771RxSight, Inc.34
Completed
Not Applicable
Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years OldAmblyopiaNCT00669539Jaeb Center for Health Research156
Completed
Not Applicable
Comparison of Femto-laser and Manually Created Clear Corneal Incisions During Cataract SurgeryCataractNCT04082273Ziemer Ophthalmic Systems AG80